Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction.
Lloberas N, Grinyó JM, Colom H, Vidal-Alabró A, Fontova P, Rigo-Bonnin R, Padró A, Bestard O, Melilli E, Montero N, Coloma A, Manonelles A, Meneghini M, Favà A, Torras J, Cruzado JM. Lloberas N, et al. Among authors: colom h. Kidney Int. 2023 Oct;104(4):840-850. doi: 10.1016/j.kint.2023.06.021. Epub 2023 Jun 28. Kidney Int. 2023. PMID: 37391040 Free article. Clinical Trial.
Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
Caldés A, Colom H, Armendariz Y, Garrido MJ, Troconiz IF, Gil-Vernet S, Lloberas N, Pou L, Peraire C, Grinyó JM. Caldés A, et al. Among authors: colom h. Antimicrob Agents Chemother. 2009 Nov;53(11):4816-24. doi: 10.1128/AAC.00085-09. Epub 2009 Sep 8. Antimicrob Agents Chemother. 2009. PMID: 19738014 Free PMC article. Clinical Trial.
Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A, Gil-Vernet S, Armendariz Y, Colom H, Pou L, Niubó J, Lladó L, Torras J, Manito N, Rufí G, Grinyó JM. Caldés A, et al. Among authors: colom h. Transpl Infect Dis. 2010 Jun;12(3):204-12. doi: 10.1111/j.1399-3062.2009.00481.x. Epub 2009 Dec 9. Transpl Infect Dis. 2010. PMID: 20002612 Clinical Trial.
Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study.
Llaudó I, Colom H, Giménez-Bonafé P, Torras J, Caldés A, Sarrias M, Cruzado JM, Oppenheimer F, Sánchez-Plumed J, Gentil MÁ, Ekberg H, Grinyó JM, Lloberas N. Llaudó I, et al. Among authors: colom h. Transpl Int. 2013 Feb;26(2):177-86. doi: 10.1111/tri.12018. Epub 2012 Dec 7. Transpl Int. 2013. PMID: 23216707 Free article.
Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
Padullés A, Colom H, Bestard O, Melilli E, Sabé N, Rigo R, Niubó J, Torras J, Lladó L, Manito N, Caldés A, Cruzado JM, Grinyó JM, Lloberas N. Padullés A, et al. Among authors: colom h. Antimicrob Agents Chemother. 2016 Mar 25;60(4):1992-2002. doi: 10.1128/AAC.02130-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26824942 Free PMC article. Clinical Trial.
64 results